Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | ALK fusion ALK G1202R |
Therapy | NVL-655 |
Indication/Tumor Type | lung non-small cell carcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ALK fusion ALK G1202R | lung non-small cell carcinoma | predicted - sensitive | NVL-655 | Phase I | Actionable | In a Phase I trial (ALKOVE-1), NVL-655 treatment demonstrated activity in patients with ALK-positive non-small cell lung cancer (including patients with ALK fusion with or without secondary ALK mutations), with a response rate of 76% (22/29), a median duration of response (DOR) of 14.4 mo, DOR greater than 6 months in 88% of patients, and a response rate of 83% (10/12) at the RP2D dose of 150mg in patients harboring an ALK fusion with ALK G1202R (Ann Oncol (2024) 35 (suppl_2): S802-S803; NCT05384626). | detail... |
PubMed Id | Reference Title | Details |
---|---|---|
1253O Phase I/II ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumours | Full reference... |